Page 31 - Cell Stem News Today

Here are the best science and tech breakthroughs, from fields like AI and space travel, that made 2021 a big year for exploration.

News and commentary from the endocrinology world

ViaCyte says its treatment helped some type 1 diabetics produce their own insulin in an ongoing clinical trial. But the company now must reproduce and expand on the finding.

SAN FRANCISCO, Dec. 2, 2021 /PRNewswire/ -- At the earliest stages of a new human life, cells that seem identical begin to divide into distinct types that eventually grow into a diverse array...

Two research groups have reported on a multicenter clinical trial that demonstrate insulin secretion from implanted cells in patients with type 1 diabetes. The study grafts pancreatic endoderm cells derived from human pluripotent stem cells (PSCs) under the skin in 26 patients. While the insulin secreted by the implants did not have clinical effects in the patients, the results offer evidence of the possibility of meal-regulated insulin secretion by differentiated stem cells in human patients.

Dr. David Thompson, Endocrinologist at Vancouver General Hospital, is the Site Principal Investigator for the ViaCyte Trial. It's a breakthrough study that shows stem cell-based implants are successful in patients with Type 1 Diabetes.

/PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with...

/PRNewswire/ -- ViaCyte, Inc., a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with...

In the first study of its kind, a team of researchers at the University of British Columbia’s faculty of medicine and Vancouver Coastal Health (VCH

We're not there yet, but there seems to be a lot of promise in this idea.